Illumina, CRISPR, Orexigen, Ambry & More
Summary
West Coast Bio Roundup: Illumina, CRISPR, Orexigen, Ambry & More Xconomy San Francisco — El Niño-driven storms returned to California this week to fill up reservoirs and snarl commutes, although we’ve got nothing to compare with what’s happening down South.—There was more fallout this week from San Diego-based Orexigen’s (NASDAQ: OREX) ill-fated decision last year to file a patent application based on a premature evaluation of a trial weighing the cardiovascular side effects of its weight-loss drug Contrave.The company, run by Novartis and Onyx Pharmaceuticals veteran Pablo Cagnoni, is working on treatments for cancer and autoimmune diseases, with its lead candidate set to enter clinical trials in 2017.—San Diego’s AnaptysBio, a developer of antibody-drug candidates to treat inflammation and cancer, said it has begun dosing human patients with an experimental drug for severe adult asthma and peanut allergies.—Xoma (NASDAQ: XOMA) of Berkeley, CA, said this week it would pull the plug on its lead drug candidate, gevokizumab, and lay off half its staff, the San Francisco Business Times reported.
Classifications
AskAI Classifications
LabelsLinked Companies
